ProQR Therapeutics (PRQR) Non-Current Deferred Tax Liability (2022 - 2025)

ProQR Therapeutics (PRQR) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $2.9 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 12.61% year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (down 12.61% YoY) and the FY2025 annual result came in at $2.9 million, down 12.61% from the prior year.
• Non-Current Deferred Tax Liability fell to $2.9 million in Q4 2025 per PRQR's latest filing, from $3.4 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for PRQR reached as high as $4.3 million in Q4 2023 and fell as low as $2.9 million in Q4 2025.
• A 4-year average of $3.7 million and a median of $3.8 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability climbed 0.27% — and 2024, when it declined 21.27%.
• Year by year, Non-Current Deferred Tax Liability stood at $4.3 million in 2022, then climbed by 0.27% to $4.3 million in 2023, then dropped by 21.27% to $3.4 million in 2024, then decreased by 12.61% to $2.9 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.9 million, $3.4 million, and $4.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.